HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
Male subjects with cardiomyopathy secondary to Duchenne muscular dystrophy (DMD) meeting all
inclusion and no exclusion criteria will be randomized. All subjects will be at least 12
years of age. They will be randomized in a 1:1 manner to either intracoronary infusion of
CAP-1002 in three coronary arteries supplying the three major cardiac territories of the left
ventricle of the heart (anterior, lateral, inferior/posterior) or usual care. In the active
treatment arm, all three major cardiac territories will be treated (infused) during a single
procedure in an open-label fashion.